Carmen Oi Ning Leung

Carmen Oi Ning Leung

Auto-generated profile, based on publicly available information

Carmen Oi Ning Leung

Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMartina Mang Leng Lei
Martina Mang Leng Lei
CLCarmen Oi Ning Leung
Carmen Oi Ning Leung
RLRainbow Wing Hei Leung
Rainbow Wing Hei Leung
XWXue Qian Wu
Xue Qian Wu
KCKatherine Po Sin Chung
Katherine Po Sin Chung
KLKin Wah Terence Lee
Kin Wah Terence Lee
Increasing evidence indicates that activation of oncogenic pathways contributes to an unfavourable tumour immune microenvironment (TIME), ultimately resulting in resistance to immunotherapy. Here, we aim to identify a critical oncogenic pathway involved in an antigen-expressing c-MYC-lucOSOE/Tp53KO hepatocellular carcinoma (HCC) mouse model that simulates immune response against tumour-associated antigens. Using data-independent acquisition proteomics, we reveal the role of wild-type KRAS in immune escaped mouse HCC tumours, with EGF concurrently activating EGFR/MEK/ERK signalling. Single cell RNA sequencing data analysis reveals that KRAS signalling intrinsically inhibits interferon-mediated MHC-I expression and extrinsically impairs CD8+ T cell activity due to the suppression of CXCL9 through the EGFR/MEK/ERK pathway. We observe KRAS activation in HCC patients who received immune checkpoint inhibitor (ICI) treatments, where it correlates with poor clinical outcomes. Notably, combination therapy with SOS1 inhibitor MRTX0902, Trametinib, and anti-PD-1 antibody effectively increased intratumoural CD8+ T cell infiltration and improved survival. Our study thus reveals that targeting wild-type KRAS signalling in combination with ICIs may serve as an effective treatment strategy for advanced HCC patients.

29 July 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CGCatherine Yu Jia Gu
Catherine Yu Jia Gu
CLCarmen Oi Ning Leung
Carmen Oi Ning Leung
RLRainbow Wing Hei Leung
Rainbow Wing Hei Leung
WCWing Ki Chau
Wing Ki Chau
MLMartina Mang Leng Lei
Martina Mang Leng Lei
KLKin Wah Terence Lee
Kin Wah Terence Lee
Lenvatinib has been approved by the FDA as a front-line treatment for advanced hepatocellular carcinoma (HCC), but its survival benefits are limited by acquired drug resistance. In this study, we investigate the mechanisms underlying lenvatinib resistance in HCC by establishing lenvatinib-resistant (LenR) patient-derived tumor xenograft (PDTX) and analyzing their genetic profiles via single-cell RNA sequencing (scRNA-seq). Through single-cell regulatory network inference and clustering (SCENIC) analysis, we find that Annexin A1 ( ANXA1 ) is significantly enriched in LenR HCC clusters. Using knockdown and overexpression strategies, we demonstrate the critical role of ANXA1 in regulating cancer stemness-driven lenvatinib resistance. ANXA1 mediates resistance by regulating S100A6 expression, while its expression is regulated by SOX2 via promoter activation, forming a positive feedback loop with STAT3. Notably, we reveal that ANXA1 secreted from LenR HCC cells reshapes the tumor microenvironment (TME) by inducing M2 macrophage polarization via FPR2 binding and activation of ERK and NF-κB signaling, leading to decreased T cell infiltration. Targeting ANXA1 via an adeno-associated virus serotype 8 (AAV8) approach improves lenvatinib efficacy in our LenR Tp53 KO / Myc OE HCC mouse model, accompanied by the suppression of an immunosuppressive TME. In conclusion, HCC-derived ANXA1 regulates lenvatinib resistance both intrinsically and extrinsically. Targeting the SOX2/ANXA1/STAT3/S100A6 positive loop may provide a novel therapeutic strategy for HCC treatment.